Patents by Inventor Richard C. K. Yen

Richard C. K. Yen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190160312
    Abstract: The present technology essentially is a portable fire damage reducing system and method including a fluid system for storing or dispensing a fluid. The fluid system can include a head unit, a body unit and a tail unit. The head unit can include a first end connectable to a fluid source. The body unit can include a first end connectable to a second end of the head unit, and a second end. The body unit can be configured to store fluid or to deliver fluid. The tail unit can include a first end connectable to the second end of the body unit, and a second end having a configuration capable of being open to the atmosphere for dispensing the fluid from the body unit or connected to the first end of the head unit to form a closed looped system with the fluid stored in the body unit.
    Type: Application
    Filed: November 28, 2018
    Publication date: May 30, 2019
    Inventor: Richard C.K. Yen
  • Publication number: 20180021264
    Abstract: The present invention relates to a product, method of making and method of using an albumin sphere suspension for controlling bleeding of a non-thrombocytopenic patient before, during and after surgery. An albumin sphere suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of controlling bleeding in vivo. The suspension is prepared by mixing at near freezing temperatures an albumin solution, a sub-stabilizing concentration of glutaraldehyde solution and an alcohol solution containing a stabilizing concentration of glutaraldehyde. The mixed suspension is warmed, and glycine and sorbitol being added. Lyophilization of the suspension can be performed for stabilization of the suspension.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 25, 2018
    Inventor: Richard C. K. Yen
  • Publication number: 20170128545
    Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.
    Type: Application
    Filed: August 10, 2016
    Publication date: May 11, 2017
    Inventor: Richard C. K. Yen
  • Patent number: 9629931
    Abstract: The present invention is associated with a method of evaluating platelet function in vivo using skin-irradiation and nanoparticle radiation treatment. The present invention in the recovery of radiation skin injury suggests that radiation skin injury can be used as a substitute model to evaluate platelet substitute products instead of measuring bleeding times. Submicron nanoparticles and a future platelet treatment product are administered intravenously before and after irradiation to subjects. The resultant radiation skin injury are compared and used to evaluate the effectiveness of the platelet treatment product on platelet function in vivo. The radiation skin injury can serve as a model to evaluate platelet and platelet-substitute products, by replacing bleeding time measurements.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 25, 2017
    Inventor: Richard C. K. Yen
  • Publication number: 20160375105
    Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.
    Type: Application
    Filed: August 10, 2016
    Publication date: December 29, 2016
    Inventor: Richard C. K. Yen
  • Publication number: 20160354481
    Abstract: A composition and a method effective in the production of the composition. The composition is a ready-to-use aqueous suspension in large and small quantities comprising human-fibrinogen-coated human-albumin spheres and the supernatant, said suspension being useful for the treatment of thrombocytopenic patients.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 8, 2016
    Inventor: Richard C. K. Yen
  • Patent number: 9504641
    Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 29, 2016
    Inventor: Richard C. K. Yen
  • Patent number: 9351925
    Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: May 31, 2016
    Inventor: Richard C. K. Yen
  • Publication number: 20160082086
    Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient. The protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor.
    Type: Application
    Filed: November 27, 2015
    Publication date: March 24, 2016
    Inventor: Richard C.K. Yen
  • Publication number: 20160045573
    Abstract: The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the patient. The protein spheres are bound with fibrinogen molecules in vitro or in vivo. The fibrinogen-coated albumin spheres provide improved hemostatic function of a residual concentration of platelets of the patient resulting in decreasing mortality rate or decreasing morbidity of the patient. The fibrinogen-coated albumin spheres protect an endothelial function of an endothelial cell of a blood vessel of the patient resulting in improved permeability control across predetermined tissues in the patient, thereby counteracting an effect of the hemorrhagic virus on a wall of the blood vessel.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventor: Richard C.K. Yen
  • Patent number: 9226898
    Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient, wherein the protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: January 5, 2016
    Inventor: Richard C. K. Yen
  • Patent number: 9114127
    Abstract: A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: August 25, 2015
    Inventor: Richard C. K. Yen
  • Publication number: 20140212358
    Abstract: The present invention is associated with a method of evaluating platelet function in vivo using skin-irradiation and nanoparticle radiation treatment. The present invention in the recovery of radiation skin injury suggests that radiation skin injury can be used as a substitute model to evaluate platelet substitute products instead of measuring bleeding times. Submicron nanoparticles and a future platelet treatment product are administered intravenously before and after irradiation to subjects. The resultant radiation skin injury are compared and used to evaluate the effectiveness of the platelet treatment product on platelet function in vivo. The radiation skin injury can serve as a model to evaluate platelet and platelet-substitute products, by replacing bleeding time measurements.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 31, 2014
    Inventor: Richard C.K. Yen
  • Publication number: 20140030347
    Abstract: A composition and a method effective in the production of the composition. The composition is a ready-to-use aqueous suspension in large and small quantities comprising human-fibrinogen-coated human-albumin spheres and the supernatant, said suspension being useful for the treatment of thrombocytopenic patients.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 30, 2014
    Inventor: Richard C.K. Yen
  • Publication number: 20130064865
    Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 14, 2013
    Inventor: Richard C.K. Yen
  • Publication number: 20130064864
    Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro.
    Type: Application
    Filed: September 6, 2012
    Publication date: March 14, 2013
    Inventor: Richard C.K. Yen
  • Publication number: 20110251127
    Abstract: A method of inactivation of infectious agents in a fluid containing plasma protein and potentially containing at least one infection agent which includes unique steps of placing the fluid in a container which is resistant to leakage under high pressure, placing the container in a compression chamber, pressurizing the fluid inside the container to a pressure sufficient to inactivate the potential infectious agent, pressurizing the fluid under a high pressure for a time duration sufficient to inactivate the potential infectious agent and pressurizing the fluid under the high pressure at an initial temperature that does not inactivate coagulation factors under the conditions. The present invention also includes a fluid containing plasma proteins which is pressurized to inactivate infectious agents, the plasma proteins containing serum albumen and at least one coagulation factor.
    Type: Application
    Filed: May 26, 2011
    Publication date: October 13, 2011
    Inventor: Richard C.K. Yen
  • Publication number: 20090304804
    Abstract: A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.
    Type: Application
    Filed: April 22, 2008
    Publication date: December 10, 2009
    Inventor: Richard C.K. Yen
  • Publication number: 20020142046
    Abstract: Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.
    Type: Application
    Filed: January 8, 2002
    Publication date: October 3, 2002
    Inventor: Richard C.K. Yen
  • Patent number: 6391343
    Abstract: The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.
    Type: Grant
    Filed: April 10, 1998
    Date of Patent: May 21, 2002
    Assignee: Hemosphere, Inc.
    Inventor: Richard C. K. Yen